Mrs Rebecca Bishop

Mrs Rebecca Bishop

Institute of Cancer and Genomic Sciences
Trial Management Team Leader
Precision Health Technologies Accelerator Industry Hub Lead

Contact details

Email
r.j.bishop@bham.ac.uk
Twitter
@beckybishop_14
Address
Cancer Research UK Clinical Trials Unit
Institute of Cancer and Genomic Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT

Rebecca Bishop is the Haematology and the IMPACT Programme Team Leader in the Cancer
Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, at the University of Birmingham.

Qualifications

BSc, Psychology & American Studies, Keele University, 2006

Biography

Rebecca Bishop graduated with a Bachelors of Science, Honours in Psychology & American Studies dual honours degree in 2006.

Rebecca worked in clinical research in infectious diseases in the NHS for 4 years. She joined the CRCTU at the University of Birmingham as a Trial Coordinator in 2013 and was promoted to Senior Trial Coordinator at the CRCTU in 2015. Her experience is in both early and late phase trials of haematological malignancies and across paediatric and adult settings.

She was appointed to Haematology Trial Management Team Leader for the IMPACT: Stem Cell transplant portfolio at the CRCTU in 2020.

In November 2022, Rebecca was appointed as Industry Hub Lead for the Precision Health Technologies Accelerator. 

Teaching

Clinical Trials - MSc/Diploma/Certificate - Clinical Trial Management: Maximising Effectiveness

Research

Rebecca Bishop has contributed to the design, set-up and/or management of the following trials:

  • BUBBLE (Myeloma)
  • CyCLLe (Chronic Lymphocytic Leukaemia)
  • CALIBRE (Chronic Lymphocytic Leukaemia)
  • ICICLLE (Chronic Lymphocytic Leukaemia)
  • CLARITY (Chronic Lymphocytic Leukaemia)
  • Matchpoint (Chronic Myeloid Leukaemia)
  • PHAZAR (Accelerated phase Myeloproliferative Neoplasms)
  • TAMARIN (Myeloproliferative Neoplasms)
  • ELASTIC (Myelodysplastic syndrome)
  • MAJIC (Myeloproliferative Neoplasms)
  • RAvVA (Acute Myeloid Leukaemia/ Myelodysplastic syndrome)
  • ROMAZA (Acute Myeloid Leukaemia)
  • De-Iron (Myelodysplastic syndrome)
  • BaP (MDS/NHL/CLL)
  • ORACLE (Peripheral T Cell Lymphoma)
  • MoTD (Graft vs Host Disease)
  • IPANEMA (Myeloma)
  • AMADEUS (Acute Myeloid Leukaemia/ Myelodysplastic syndrome)
  • COSI (Acute Myeloid Leukaemia/ Myelodysplastic syndrome)
  • COVID19-BMT (COVID19/Haematological Malignancies)
  • ALL-RIC (Acute Lymphoblastic Leukaemia)

Publications

Buckham, J., Faville, R., Bowden, S.J., Beety, J., Burke, A., & Kearns, P. “Developing a model for shared care participation in paediatric oncology clinical trials” 14th International Paediatric Haematology and Oncology update meeting, Edinburgh, 1st May 2014. 

Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., Dyer, M. J. S., Fegan, C., Oscier, D., Pettitt, A., Matutes, E., Devereux, S., Allsup, D., Bloor, A., Hillmen, P., Follows, G., Rule, S., Moss, P. and Stankovic, T. (2017), A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. Br J Haematol. doi:10.1111/bjh.14793. 

Jim Murray, Guy Pratt, Abe Jacob, Fiona Clark, Rachel Blundred, Sonia Fox, Rebecca Bishop, Keith Wheatley, Farhat Khanim, Chris Bunce, Mark Drayson, “Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers” Contemporary Clinical Trials Communications 14 (2019) 100361. 

Peter Hillmen, Andy C. Rawstron, Kristian Brock, Samuel Muñoz-Vicente, Francesca J. Yates, Rebecca Bishop, Rebecca Boucher, Donald MacDonald, Christopher Fegan, Alison McCaig, Anna Schuh, Andrew Pettitt, John G. Gribben, Piers E.M. Patten, Stephen Devereux, Adrian Bloor, Christopher P. Fox, Francesco Forconi, and Talha Munir “Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study” Journal of Clinical Oncology. DOI: 10.1200/JCO.19.00894.